Clinical characteristics of varian cancer patients with survival time over 3 years and its influencing factors of prognosis

ZHU Yaodong; ZHANG Mei; LI Ping

doi:10.7619/jcmp.201909006

Journal of Clinical Medicine in Practice > 2019 > 23(9): 20-23. > DOI: 10.7619/jcmp.201909006

ZHU Yaodong, ZHANG Mei, LI Ping. Clinical characteristics of varian cancer patients with survival time over 3 years and its influencing factors of prognosis[J]. Journal of Clinical Medicine in Practice, 2019, 23(9): 20-23. DOI: 10.7619/jcmp.201909006

Citation:

PDF (627 KB)

Clinical characteristics of varian cancer patients with survival time over 3 years and its influencing factors of prognosis

Chinese and Western Medicine Department for Oncology, First Affiliated Hospital of Medical University of Anhui, Hefei, Anhui, 230000

More Information

Received Date: February 19, 2019
Accepted Date: March 24, 2019
Available Online: December 21, 2020
Published Date: May 14, 2019

Graphical Abstract

Abstract

Abstract

Objective To explore the clinical characteristics of varian cancer patients with survival time over 3 years with and its influencing factors of prognosis.
Methods The clinical data of 87 patients with ovarian malignancy were analyzed retrospectively, and the clinical characteristics and its influencing factors of prognosis were observed.
Results The average age of 87 patients with ovarian cancer was (52.58±10.23) years old. According to the survival time, they were divided into the survival time >3 years group (n=54) including 17 deaths and 37 survival patients and the survival time ≤3 years group (n=33) including 22 deaths and 11 survival patients. At last, a total of 76 patients were included in the study except for 11 survival patients with survival time ≤3 years. Kaplan-Meier survival analysis and Cox multiple factor survival analysis showed that operation, clinical staging, Karnofsky function and status(KPS) scores, cycles of chemotherapy, the use of traditional Chinese medicine were the prognostic factors of patients with ovarian cancer.
Conclusion Early diagnosis, operation treatment thoroughly, specification, sufficient and multiple courses of chemotherapy, combined with traditional Chinese medicinal treatment can prolong the survival time of patients with ovarian cancer.
- ovarian cancer,
- clinical characteristics,
- prognosis,
- survival time

FullText(HTML)

References (13)

References

[1]	Matulonis U A. Management of newly diagnosed or recurrent ovarian cancer[J]. Clin Adv Hematol Oncol, 2018, 16(6): 426-437. http://www.ncbi.nlm.nih.gov/pubmed/30067614
[2]	Kim J Y, Cho C H, Song H S. Targeted therapy of ovarian cancer including immune check point inhibitor[J]. Korean J Intern Med, 2017, 32(5): 798-804. doi: 10.3904/kjim.2017.008
[3]	Dong X, Men X, Zhang W, et al. Advances in tumor markers of ovarian cancer for early diagnosis[J]. Indian J Cancer, 2014, 51(Suppl 3): e72-e76. http://www.ncbi.nlm.nih.gov/pubmed/25818738
[4]	Heidemann L N, Hartwell D, Heidemann C H, et al. The relation between endometriosis and ovarian cancer-a review[J]. Acta Obstet Gynecol Scand, 2014, 93(1): 20-31. doi: 10.1111/aogs.12255
[5]	林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014: 448-448.
[6]	卢淮武, 林仲秋. 2018 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南[J]. 中国实用妇科与产科杂志, 2018, 34(5): 526-536. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201805016.htm
[7]	Jiang Y H, He W F, Yang H, et al. Analysis of clinical effects of neoadjuvant chemotherapy in advanced epithelial ovarian cancer[J]. J BUON, 2018, 23(3): 758-762. http://www.ncbi.nlm.nih.gov/pubmed/30003748
[8]	Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress[J]. Clin Epigenetics, 2019, 11(1): 7-17. doi: 10.1186/s13148-018-0602-0
[9]	Bommert M, Harter P, Heitz F, et al. When should surgery be used for recurrent ovarian carcinoma[J]. Clin Oncol (R Coll Radiol), 2018, 30(8): 493-497. doi: 10.1016/j.clon.2018.04.006
[10]	Ben-Arye E, Lavie O, Samuels N, et al. Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach[J]. Med Oncol, 2017, 34(4): 54-54. doi: 10.1007/s12032-017-0910-9
[11]	刘新敏, 朴炳奎. 朴炳奎治疗卵巢癌经验[J]. 中医杂志, 2015, 56(22): 1907-1909. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201522007.htm
[12]	黄宏, 沈敏鹤, 阮善明, 等. 吴良村治疗卵巢癌经验[J]. 中医杂志, 2017, 58(9): 737-740. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201709005.htm
[13]	李平. 对肿瘤病因、致病特点的再认识[J]. 中国中西医结合杂志, 2018, 38(2): 160-162. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201802008.htm

[1]	SHEN Yi, JING Ying. Efficacy of Aiyu Capsule combined with FOLFOX4 chemotherapy in treatment of median or advanced rectum cancer and its impacts on cellular immunity and survival[J]. Journal of Clinical Medicine in Practice, 2024, 28(23): 58-64. DOI: 10.7619/jcmp.20242114
[2]	HUANG Xiaoli, HUANG Xiaoyan, SONG Shuhui, ZHANG Ying. Correlations of prognostic nutritional index and modified Glasgow prognostic score with prognosis in patients with cervical cancer[J]. Journal of Clinical Medicine in Practice, 2024, 28(20): 12-17. DOI: 10.7619/jcmp.20233927
[3]	GAO Qingling, CHANG Yan, WANG Jingni, ZHANG Jing, SUN Qingke. Effects of individual or combination medication of epidermal growth factor receptor tyrosine kinase inhibitor combined with chemotherapy on progression-free survival in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation[J]. Journal of Clinical Medicine in Practice, 2023, 27(24): 1-6. DOI: 10.7619/jcmp.20233042
[4]	WU Yang, YUAN Chengjia, YANG Die, ZHANG Xiaochun. Effect of Shenmai Injection on survival of patients with gastric cancer in phase Ⅱ to Ⅲ based on propensity score matching[J]. Journal of Clinical Medicine in Practice, 2023, 27(14): 46-50, 57. DOI: 10.7619/jcmp.20231064
[5]	LIU Shenxiang, XU Yongcheng, YAN Xuebing, MAO Haiyan, YE Qian. Influence of clinicopathological characteristics of elderly patients with left and right colon cancer on prognosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(4): 113-116, 122. DOI: 10.7619/jcmp.20223286
[6]	WU Haoming, FU Guangbo. Clinical significance of long non-coding RNA SChLAP1 expression in prostate cancer tissue and its relationship with prognosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 30-33. DOI: 10.7619/jcmp.20214427
[7]	WU Xin, LIANG Bo. Construction of a postoperative survival nomogram for breast cancer based on ultrasound and cancer indicators[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 62-68. DOI: 10.7619/jcmp.20213928
[8]	XING Haiyang, ZHANG Yandi, WANG Kexin. Analysis on effect of radiotherapy on the survival of cervical cancer based on SEER database[J]. Journal of Clinical Medicine in Practice, 2020, 24(6): 15-19. DOI: 10.7619/jcmp.202006005
[9]	ZHANG Wei. Application of TIME-H principles in holistic nursing for patients with chronic venous ulcers in lower limbs[J]. Journal of Clinical Medicine in Practice, 2016, (14): 56-58. DOI: 10.7619/jcmp.201614018
[10]	XING Ze, WANG Hua, HU Qun, ZHAO Haiyan, SU Wuyun. Risk factors and survival analysis of locally advanced non-small cell lung cancer with brain metastasis[J]. Journal of Clinical Medicine in Practice, 2015, (23): 24-27. DOI: 10.7619/jcmp.201523008

Cited By

Cited by

Periodical cited type(3)

1.	费晓舟，金淦，马玉亮. 利伐沙班对腹腔镜疝修补术后出血和血栓形成的影响. 中国药物应用与监测. 2024(04): 438-441 .
2.	王琳，尚文强，李艳蔚. 肩关节镜不同入路方式在创伤性肩关节脱位中的应用效果及安全性. 临床误诊误治. 2023(01): 90-94 .
3.	邵超，高文灿，张军，沈滨，许建伟，殷凯. 普通外科术后下肢深静脉血栓形成预测模型的建立. 实用临床医药杂志. 2022(22): 12-15+19 . 本站查看

Other cited types(1)

Get Citation

PDF

XML

Article views (495) PDF downloads (11) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Clinical characteristics of varian cancer patients with survival time over 3 years and its influencing factors of prognosis